Royalty Report: Drugs, Therapeutic, Disease – Collection: 253

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 13

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • HIV / AIDs
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 253

License Grant
Licensor grants Swiss Licensee a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Compounds and Products under the Licensee Proprietary Rights and Licensees’ part of the Joint Patents.
License Property
The Parties have previously entered into (a) a Development and License Agreement (including its Appendices) dated as of the 1st day of July 1999, as amended by the Amendment to the Development and License Agreement (DLA First Amendment) executed July 12, 2004 and rescinded and voided ab initio on July 12, 2004 by the Rescission of the Amendment to the Development and License Agreement (Rescission) and the Letter of Amendment (DLA Second Amendment) effective September 20, 2005.

Product relates to brand name Fuzeon® in indications other than the treatment of HIV.  Fuzeon was developed in collaboration with the Licensee, and is our only currently marketed product.  Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.  The FDA approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.

Date U.S. Pat. No. 5,464,933 11/7/95 Synthetic Peptide Inhibitors of HIV Transmission 6/7/2013
U.S. Patent No. 6,133,418 10/17/00 Synthetic Peptide Inhibitors of HIV Transmission 11/17/2014
U.S. Patent No. 6,475,491 11/5/02 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/7/2015
U.S. Patent No. 6,861,059 3/1/05 Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations 9/9/2015
Canadian Patent No. 2,224,008 8/18/09 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/6/2016
U.S. Patent No. 6,281,331 8/28/01 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,015,881 1/18/00 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,824,783 11/30/04 Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission 11/30/2021

Field of Use
Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, the Licensor's first and only commercial product, Fuzeon (whose generic name is enfuvirtide, originally known as T-20), offers a novel mechanism of action to treat and potentially prevent the transmission of HIV.

IPSCIO Record ID: 6950

License Grant
Under our Development and License Agreement Licensee has an exclusive License to manufacture and sell Fuzeon worldwide.
License Property
Fuzeon is our first-generation HIV fusion inhibitor, developed in collaboration with the Licensee. Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.
Field of Use
The Food and Drug Administration approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.

IPSCIO Record ID: 1206

License Grant
The Licensor entered into a Development and License Agreement with the Licensee to develop and commercialize T-20, currently marketed as Fuzeon, whose generic name is enfuvirtide, and T-1249, or a replacement compound.

The Development and License Agreement has been amended several times; most recently in March 2007, the Agreement was amended to cover only the development and commercialization of Fuzeon.

License Property
The returned intellectual property covers both research and development stage molecules, including T-1249.

The Licensor is a biopharmaceutical company primarily engaged in the commercialization of a new class of antiviral drug treatments called fusion inhibitors. Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, our first commercial product and our development-stage compound offer a novel mechanism of action to treat and potentially prevent the transmission of HIV.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 26496

License Grant
Licensor  hereby grants to Licensee an exclusive, worldwide license to practice under the patent rights and to make, have made, use, lease, offer to sell, sell and import the licensed products and to practice the licensed processes, to the full end of the term for which the patent rights are granted, unless sooner terminated as hereinafter provided, said license to include the right to sublicense and to be exclusive to Licensee subject only to any license heretofore granted to the United States government.
License Property
Fuzeon, a 36 amino acid synthetic peptide, is our first drug candidate for HIV fusion inhibition. Fuzeon has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.

U.S. Patent No. 5,444,044- For: Synthetic Polypeptides As Inhibitors Of HIV-1

Field of Use
The rights granted apply to the medical field.

IPSCIO Record ID: 27851

License Grant
The Licensees entered into a settlement agreement with licensor resolving the litigation over Fuzeon currently pending in the U.S. District Court for the Eastern District of North Carolina. Under the terms of the Settlement Agreement, the Licensee collaboration will continue to sell Fuzeon under a license to Licensor's U.S. patent No. 7,285,271 B1. Fuzeon®, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors.
License Property
Fuzeon (enfuvirtide) is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in people who have not responded well enough to other antiviral medications.
Field of Use
The rights granted apply to the healthcare industry for humans.

IPSCIO Record ID: 26363

License Grant
The Company entered into a worldwide exclusive patent license agreement with the Licensor, government public health organization, concerning composition of matter for BlockAide/CR.
License Property
BlockAide/CR&#-3884; is a peptide-based drug that is intended to work by blocking viral entry and infection of human immune system cells.

The patents covering a peptide product, known as BlockAide, for the treatment and prevention of HIV.

Field of Use
The rights granted apply to the medical industry relating to human infections.

IPSCIO Record ID: 243453

License Grant
Pursuant to a previous agreement, the parties entered into a collaboration for the worldwide development and marketing of a Product 1 and a Product 2 as drugs for the treatment of HIV infection from among proprietary compounds of Licensor.

Licensor grants a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Drug Candidates and Joint Products under Licensors part of the Joint Research Patents and any rights licensed by Licensor to Licensee in the License Agreement which also cover such Drug Candidate or Joint Products.

Licensee shall have the right to sublicense the rights granted in the Field to any third party.

License Property
Type I Drug Candidate shall mean any Peptide which is covered by the Licensors Patents and had been identified by Licensor prior to July 1, 1999 and are listed in Licensors Peptide Database.

Type II Drug Candidate shall mean any Peptide which is covered by the Licensors Patents and is identified by Licensor or Licensee after July 1, 1999.

'Peptide' shall mean a peptide, peptoid, or peptidomimetic of molecular weight greater than 2000 Daltons.

Field of Use
Field shall mean Peptides for use in the treatment of HIV infection which inhibit fusion by interaction with HIV gp41.

IPSCIO Record ID: 289184

License Grant
Foundation grants to Licensee the exclusive right and license to make, have made, use, import, offer for sale, and sell in the Territory, Licensed Products during the term of this Agreement including Licensee’s right to grant sublicenses.

The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.

License Property
Licensed Product means any compound, product, service, or process in the Field, the manufacture, use, or sale of which, but for the license granted herein, would infringe at least one Valid Claim.

Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.
7,250,421 – Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase

Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).

Field of Use
Field means any and all anti-viral uses, including but not limited to prophylaxis, diagnosis or treatment of a condition, infection or disease associated with a virus, except the Field specifically excludes any anti-viral use associated with (a) the following DNA virus families:  poxviridae, polyomaviridae, papillomaviridae, adenoviridae, and parvoviridae; and (b) all RNA viruses except for the following RNA virus families, which are specifically included in the Field:  retroviridiae (for example HIV as defined below), flaviviridae (for example HCV as defined below), orthomyxoviridae, paramyxoviridae, and coronaviridae. In the event that Licensee terminates the Sponsored Research Agreement (“SRA”), a copy of which is attached as Appendix J, pursuant to paragraph 16(d) of the SRA, the Field of this License Agreement shall automatically be amended to exclude HCV.

IPSCIO Record ID: 26110

License Grant
University hereby grants  a) a non-exclusive License to use the Know-How in the territory and within the Fields of Use; and b) an exclusive License to University's Patent Rights in the territory to make, use, sell, lease, offer to sell, and import any Licensed Products and to practice any Licensed Processes.
License Property
Patent Rights
· U.S. Patent No. 6,846,605 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (related to Case # CU9014H).

· U.S. Patent Application No. 11/044,224 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (Continuation application of Patent No. 6,846,605).

· Provisional Patent Application No. 60/742,191 Alpha-1-antitrypsin inhibition of disease and conditions mediated by binding to cell-associate actin (related to Case # CU1428H).

· Provisional Application No. 60/913,174 Title: Compositions and Methods of Use for Alpha­Anti Trypsin Having No Significant Serine Protease Inhibitor Activity (CU1697H US).

· PCT Application No, PCT/US2006/061577 Title: Compositions and Methods For Treating Actin-Mediated Conditions (CU1428H).

· U.S. Patent Application No.11/719,200 Compositions and Methods For Treating Actin- Mediated Conditions (CU1428H US1).

Field of Use
Fields of Use: use of alpha-1 antitrypsin, and any analogs thereof, including but not limited to synthetic analogs, alpha-1 antitrypsin derivatives, alpha-1 antitrypsin fragments, combinations with alpha-1 antitrypsin and modifications of alpha-1 antitrypsin, for the prevention and/or treatment including prophylaxis of, reduction of and/or reduction of symptoms related to any and all viral infections.

Treatment of all viral infections including, without limitation, any and all mutations, strains, and subtypes, including future mutations, strains, and subtypes of: Human Immunodeficiency Virus (HIV) (including any viral infections reasonably and/or previously withheld by the University, when they become available); Human Papilloma Virus (HPV); Herpes Simplex Virus (HSV); Hepacivirus; Pestivirus; Avian influenza virus; Human influenza virus; Murray Valley encephalitis; St. Louis encephalitis.

IPSCIO Record ID: 2659

License Grant
The Licensee acquired C31G Technology from the inventor of the technology, also the Licensor.
License Property
C31G is a broad-spectrum compound with antiviral, antibacterial and antifungal activity. Its mechanism of action is via immediate membrane disruption, and it is also spermicidal. Because of its mechanism of action, C31G has a low potential for resistance and is active against drug resistant pathogens.  It shows promise for use against STD's.

Savvy ® (C31G vaginal gel) is a potential microbicide for the prevention of male-to-female transmission of HIV among women at high risk of infection.  The active compound in Savvy is C31G, a broad-spectrum compound with antiviral, antibacterial and antifungal activity.

Product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally, including Savvy®, which underwent Phase 3 clinical trials in Ghana and Nigeria for reduction in the transmission of Human Immunodeficiency Virus/Acquired Immunodeficiency Disease, or HIV/AIDS, both of which were suspended in 2005 and 2006 and terminated before completion, and is the subject to a Phase 3 contraception trial in the United States.  While the Savvy Phase 3 contraception trial in the United States has been completed and the analysis of the results is expected to be completed by the end of 2009.

Field of Use
The Field of Use apply to the healthcare industry relating to Human Immunodeficiency Virus and Acquired Immunodeficiency Disease.

IPSCIO Record ID: 139546

License Grant
The Canadian Company reacquired the 50% interest in the Antibody 1F7 acquired by Licensor.
License Property
The monoclonal antibody 1F7 has several important effects on both humoral (antibody-mediated) and cellular immunity mechanisms  that make it an ideal candidate for an HIV therapy.  The anti-idiotypic antibody 1F7 selectively inhibits cytotoxic T-cells activated in HIV-1 infection.  Immunol Cell Biol 78(1), 20-7.
Field of Use
This agreement pertains to the drug industry related to its use as a therapeutic for the prevention and treatment of HIV infection.

IPSCIO Record ID: 3138

License Grant
University hereby grants to the Company an Exclusive License to make, have made, use, and sell the Licensed Product(s) and to provide the Licensed Service(s) in the United States and worldwide under the Patent Rights.
License Property
Patent Rights shall mean the U.S. patent application Serial No. 07/635,196 filed on January 2, 1991, and assigned to JHU entitled 'Method for the Inhibition and Prevention of Viral Replication Using Fusions of a Virus Protein and a Destructive Enzyme: (hereinafter the Patent Application).

Licensed Product(s) means any material, composition, drug, transducing particle, or other product, the manufacture, use or sale of which would constitute, but for the license granted to the Company pursuant to this Agreement, an infringement of a claim of Patent Rights (infringement shall include, but is not limited to, direct, contributory, or inducement to  infringe).

Field of Use
Field of Use: Method for the Inhibition and Prevention of Viral Replication Using Fusions of a Virus Protein and a Destructive Enzyme: (hereinafter the PATENT APPLICATION).

IPSCIO Record ID: 3900

License Grant
Pursuant to an exclusive license agreement, the Company was granted exclusive Licenses in perpetuity for technologies developed by Licensor for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies.

The Company and Licensor have agreed, in principle, to an amendment to the existing Licensing Agreement to include additional virus types among the virus types the Company is permitted to manufacture, use, and offer for sale, and, Licensor has permitted the Company to use its nanomaterials to develop treatments for Dengue viruses, Ebola/Marburg viruses, and viruses causing viral Conjunctivitis (a disease of the eye), until such time as the Company and Licensor can complete an amendment to the Licensing Agreement to include these additional virus types we are permitted to manufacture, use and offer for sale.

Field of Use
The rights granted apply to the healthcare industry relating to life-threatening viral infections.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.